MX2022009081A - Absorcion celular. - Google Patents
Absorcion celular.Info
- Publication number
- MX2022009081A MX2022009081A MX2022009081A MX2022009081A MX2022009081A MX 2022009081 A MX2022009081 A MX 2022009081A MX 2022009081 A MX2022009081 A MX 2022009081A MX 2022009081 A MX2022009081 A MX 2022009081A MX 2022009081 A MX2022009081 A MX 2022009081A
- Authority
- MX
- Mexico
- Prior art keywords
- acid
- bile
- salt
- edta
- human
- Prior art date
Links
- 230000004700 cellular uptake Effects 0.000 title 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 3
- 239000003613 bile acid Substances 0.000 abstract 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000003833 bile salt Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 abstract 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 abstract 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 abstract 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 abstract 1
- 229960003964 deoxycholic acid Drugs 0.000 abstract 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Hybrid Cells (AREA)
Abstract
La presente invención provee un ácido biliar, o una sal farmacéuticamente aceptable de este, para su uso en un método de tratamiento del cuerpo humano o animal, comprendiendo este método la administración de un compuesto terapéutico al cuerpo humano o animal, en donde: a. dicho ácido biliar es ácido quenodesoxicólico o ácido desoxicólico, y b. opcionalmente, dicha sal biliar se emplea junto con EDTA, c. en dicho método, el ácido o la sal biliar y EDTA se usan para hacer posible o potenciar la absorción intracelular del compuesto terapéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020900183A AU2020900183A0 (en) | 2020-01-23 | Cellular Uptake | |
| PCT/IB2021/050477 WO2021148990A1 (en) | 2020-01-23 | 2021-01-22 | Cellular uptake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009081A true MX2022009081A (es) | 2023-01-04 |
Family
ID=74494954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009081A MX2022009081A (es) | 2020-01-23 | 2021-01-22 | Absorcion celular. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230109708A1 (es) |
| EP (1) | EP4093391A1 (es) |
| JP (1) | JP2023514070A (es) |
| KR (1) | KR20220131946A (es) |
| CN (1) | CN115003293A (es) |
| AU (1) | AU2021211236A1 (es) |
| BR (1) | BR112022014529A2 (es) |
| CA (1) | CA3168207A1 (es) |
| IL (1) | IL294979A (es) |
| MX (1) | MX2022009081A (es) |
| WO (1) | WO2021148990A1 (es) |
| ZA (1) | ZA202209340B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022157676A1 (en) * | 2021-01-22 | 2022-07-28 | Axcess (UK) Ltd | Edta and egta for use in preserving the integrity of therapeutic compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1163573A (zh) * | 1994-08-31 | 1997-10-29 | 科特克斯有限公司 | 含有增加活性化合物生物利用度的胆汁盐和缓冲剂的药物组合物 |
| US5653987A (en) * | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
| GB2355009A (en) | 1999-07-30 | 2001-04-11 | Univ Glasgow | Peptides conjugated to bile acids/salts |
| GB0308734D0 (en) * | 2003-04-15 | 2003-05-21 | Axcess Ltd | Uptake of macromolecules |
| US9044381B2 (en) * | 2003-06-24 | 2015-06-02 | Baxter International Inc. | Method for delivering drugs to the brain |
| CN102078304B (zh) * | 2011-01-21 | 2012-05-30 | 中国科学院长春应用化学研究所 | 一种胰岛素载药微球及其制备方法 |
| AU2013268379B2 (en) * | 2012-05-31 | 2017-05-25 | Terumo Kabushiki Kaisha | pH-sensitive carrier and method for production thereof, pH-sensitive medicine and pH-sensitive pharmaceutical composition each containing said carrier, and culture method using said pH-sensitive medicine or said pH-sensitive pharmaceutical composition |
-
2021
- 2021-01-22 CN CN202180010872.4A patent/CN115003293A/zh active Pending
- 2021-01-22 MX MX2022009081A patent/MX2022009081A/es unknown
- 2021-01-22 EP EP21702714.3A patent/EP4093391A1/en active Pending
- 2021-01-22 IL IL294979A patent/IL294979A/en unknown
- 2021-01-22 AU AU2021211236A patent/AU2021211236A1/en active Pending
- 2021-01-22 BR BR112022014529A patent/BR112022014529A2/pt unknown
- 2021-01-22 WO PCT/IB2021/050477 patent/WO2021148990A1/en unknown
- 2021-01-22 US US17/794,757 patent/US20230109708A1/en active Pending
- 2021-01-22 CA CA3168207A patent/CA3168207A1/en active Pending
- 2021-01-22 JP JP2022544680A patent/JP2023514070A/ja active Pending
- 2021-01-22 KR KR1020227028231A patent/KR20220131946A/ko active Search and Examination
-
2022
- 2022-08-19 ZA ZA2022/09340A patent/ZA202209340B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021211236A1 (en) | 2022-08-11 |
| IL294979A (en) | 2022-09-01 |
| WO2021148990A1 (en) | 2021-07-29 |
| CN115003293A (zh) | 2022-09-02 |
| CA3168207A1 (en) | 2021-07-29 |
| US20230109708A1 (en) | 2023-04-13 |
| ZA202209340B (en) | 2023-05-31 |
| KR20220131946A (ko) | 2022-09-29 |
| EP4093391A1 (en) | 2022-11-30 |
| BR112022014529A2 (pt) | 2022-09-20 |
| JP2023514070A (ja) | 2023-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016135810A5 (es) | ||
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| RU2012145116A (ru) | Фармацевтическая композиция для предупреждения или лечения неалкогольного жирового гепатоза и способ предупреждения или лечения неалкогольного жирового гепатоза с ее использованием | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
| MX2023008726A (es) | Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual. | |
| SE0400184D0 (sv) | New therapeutical use | |
| ATE414522T1 (de) | Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure | |
| NO20055390L (no) | Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer | |
| NO20064755L (no) | Kombinasjonsterapi | |
| MX2022009081A (es) | Absorcion celular. | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| CN116406288A8 (zh) | 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法 | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| NZ588470A (en) | Pharmaceutical composition comprising a benzophenone derivative and an immunosuppressing agent for treating autoimmune diseases |